Piper Sandler analyst Joseph Catanzaro downgraded Turnstone Biologics (TSBX) to Neutral from Overweight with a price target of 40c, down from $3.75, after the company announced it is discontinuing all of its clinical studies evaluating TIDAL-01 and is exploring strategic alternatives. Piper removed all value for TIDAL-01 and downgraded the shares.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.